<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23284" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hypopituitarism</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gounden</surname>
            <given-names>Verena</given-names>
          </name>
          <aff>University of KwaZulu Natal</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Anastasopoulou</surname>
            <given-names>Catherine</given-names>
          </name>
          <aff>Jefferson Einstein Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jialal</surname>
            <given-names>Ishwarlal</given-names>
          </name>
          <aff>VA MEDICAL CENTER, MATHER , CA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Verena Gounden declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Catherine Anastasopoulou declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ishwarlal Jialal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>16</day>
          <month>9</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23284.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hypopituitarism is a medical condition characterized by insufficient hormone production in the pituitary gland. The association between hypopituitarism and increased mortality due to elevated cardiovascular and respiratory diseases highlights the crucial need for early detection. This condition often presents subtle symptoms, which, if left untreated, can lead to more severe morbidity. This activity provides a comprehensive review of the pathophysiological aspects of hypopituitarism, shedding light on its underlying mechanisms. This activity underscores the vital role of the interprofessional healthcare team in educating patients about this complex disorder. Furthermore, this activity for healthcare professionals is designed to enhance the learner's competence when managing hypopituitarism by improving the team's understanding of early recognition and appropriate diagnostic measures, ultimately improving patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Differentiate&#x000a0;among the various etiologies and underlying causes of hypopituitarism to tailor treatment approaches based on individual patient profiles.</p></list-item><list-item><p>Select the most suitable hormone replacement therapies, dosages, and administration methods based on individual patient needs and response to treatment.</p></list-item><list-item><p>Implement evidence-based treatment strategies, including hormone replacement therapy and surgical interventions, to effectively manage hypopituitarism in diverse patient populations.</p></list-item><list-item><p>Collaborate with an interprofessional healthcare team, including endocrinologists, neurosurgeons, nurses, and radiologists, to ensure comprehensive and coordinated care for hypopituitarism patients.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23284&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23284">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23284.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The pituitary gland plays a significant role in producing and secreting various hormones that regulate the body's endocrine functions. This gland is anatomically divided into 2 main lobes&#x02014;the anterior and the posterior.</p>
        <p>The anterior lobe of the pituitary gland is responsible for synthesizing and releasing several essential hormones, including growth hormone (GH), thyroid-stimulating hormone (TSH), luteinizing&#x000a0;hormone (LH), follicular-stimulating hormone (FSH), adrenocorticotropin hormone (ACTH), and prolactin (PRL).</p>
        <p>The posterior pituitary lobe is responsible for storing and releasing 2 essential hormones, including oxytocin and antidiuretic hormone (ADH), which is also called vasopressin. These hormones are synthesized by neurosecretory cells located in the hypothalamus.</p>
        <p>The regulation of pituitary gland activity is complex and involves the interaction between the hypothalamus and anterior pituitary. The hypothalamus releases and inhibits hormones, often called tropic hormones, which directly affect the secretion of specific hormones from the anterior lobe of the pituitary gland. These interactions subsequently and profoundly impact various target organs and their respective functions.</p>
        <p>Hypopituitarism is a medical condition characterized by a deficiency&#x000a0;in 1 or more of the hormones produced by the pituitary gland. This condition is associated with an increased mortality risk&#x000a0;from cardiovascular and respiratory diseases. Early detection of hypopituitarism is imperative, given its subtle symptoms that may lead to additional health complications.<xref ref-type="bibr" rid="article-23284.r1">[1]</xref><xref ref-type="bibr" rid="article-23284.r2">[2]</xref><xref ref-type="bibr" rid="article-23284.r3">[3]</xref></p>
      </sec>
      <sec id="article-23284.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Hypopituitarism can originate from 2 primary sources&#x02014;pathology of the hypothalamus, which affects the production of tropic hormones that act on the pituitary, or direct pathology within the pituitary gland itself. The predominant cause of hypopituitarism is pituitary tumors, which account for 61% of cases.&#x000a0;These&#x000a0;tumors may cause overproduction of&#x000a0;a single hormone, leading to a deficiency in other pituitary hormones. For instance, in acromegaly, an excess of GH coincides with hypopituitarism due to macroadenoma.</p>
        <p>Most pituitary tumors are benign and can be either secretory or nonsecretory. In rare cases, secondary metastases from breast, colon, and prostate cancers can also impact the pituitary gland. Hypopituitarism can also be associated with&#x000a0;hypothalamic and para-pituitary tumors, such as suprasellar meningiomas, gliomas, and craniopharyngiomas. In addition to tumors, various injuries&#x000a0;to the pituitary gland, such as traumatic brain injury, iatrogenic injury during surgery, or cranial irradiation, may also cause hypopituitarism.<xref ref-type="bibr" rid="article-23284.r4">[4]</xref></p>
        <p>Inflammatory conditions that affect the pituitary gland may also contribute&#x000a0;to the&#x000a0;development of hypopituitarism. Infectious agents associated with pituitary insufficiency include <italic toggle="yes">Mycobacterium&#x000a0;tuberculosis</italic>&#x000a0;and agents that don't belong to the genus <italic toggle="yes">Mycobacterium,</italic> such as histoplasmosis, syphilis, viruses, and protozoa.</p>
        <p>Lymphocytic hypophysitis is a specific inflammatory condition often observed in the postpartum period. This condition responds well to steroid therapy and manifests as a mass lesion on magnetic resonance imaging (MRI)&#x000a0;due to the infiltration of lymphocytes and plasma cells within the pituitary.</p>
        <p>The latest immunotherapy category involving immune checkpoint inhibitors, including cytotoxic T-lymphocytes antigen-4 (CTLA-4), programmed cell death 1 (PD-1), and programmed cell death ligand 1 (PDL-1), can cause hypophysitis. This condition is characterized by central adrenal insufficiency. On rare occasions, it may lead to central hypothyroidism or hypogonadism.<xref ref-type="bibr" rid="article-23284.r5">[5]</xref> In most cases,&#x000a0;hormonal alterations&#x000a0;can persist even after discontinuing the medication, frequently resulting in permanent changes.<xref ref-type="bibr" rid="article-23284.r6">[6]</xref><xref ref-type="bibr" rid="article-23284.r7">[7]</xref><xref ref-type="bibr" rid="article-23284.r8">[8]</xref><xref ref-type="bibr" rid="article-23284.r9">[9]</xref></p>
        <p>Infiltrative diseases such as hemochromatosis, sarcoidosis, and histiocytosis&#x000a0;have been associated with hypopituitarism development. In these conditions, abnormal deposition of substances or immune-related processes can cause damage and dysfunction of the pituitary gland, ultimately leading to hypopituitarism.</p>
        <p>Hypopituitarism induced by traumatic brain injury is one of the more recently recognized mechanisms that can result in isolated or global pituitary deficits.&#x000a0;Some studies indicate worse outcomes and minimal recovery in such cases. Although&#x000a0;a timely diagnosis can be beneficial, it is not always straightforward, as symptoms can be nonspecific and may overlap with the effects of the underlying injury.<xref ref-type="bibr" rid="article-23284.r10">[10]</xref><xref ref-type="bibr" rid="article-23284.r11">[11]</xref></p>
        <p>Pituitary apoplexy is a medical emergency that arises from acute ischemic infarction or hemorrhage within the pituitary gland. Although pituitary apoplexy generally occurs in the presence of a pituitary adenoma, it may also happen in the normal pituitary gland. Sheehan syndrome occurs due to infarction of the hyperplastic pituitary gland following significant blood loss during postpartum hemorrhage. The pituitary gland's rich and intricate vascular supply sets it apart from other brain tumors and contributes to the heightened risk of bleeding within pituitary adenomas.<xref ref-type="bibr" rid="article-23284.r12">[12]</xref></p>
        <p>Congenital absence of the pituitary gland is related to midline craniofacial defects. Genetic mutations in transcription factors, such as HESX1, PROP1, and Pit-1, can lead to congenital hypopituitarism.<xref ref-type="bibr" rid="article-23284.r13">[13]</xref><xref ref-type="bibr" rid="article-23284.r14">[14]</xref></p>
        <p>Empty Sella syndrome is a rare disorder characterized by the enlargement or malformation of the sella turcica, resulting in a herniation of the arachnoid membrane into the pituitary fossa. This displacement pushes the pituitary gland toward the floor of the fossa, potentially resulting in a more minor or absent pituitary gland. Empty Sella syndrome may be idiopathic or&#x000a0;be secondary to factors such as treated pituitary tumors, head trauma, or a condition called pseudotumor cerebri, which is also known as idiopathic intracranial hypertension.</p>
        <p>Kallmann syndrome is another rare genetic condition characterized by an inability to detect odor, also referred to as hyposmia or anosmia, and hypogonadotropic hypogonadism, marked by decreased FSH, LH, testosterone, or estradiol levels. This syndrome results from a mutation in the <italic toggle="yes">Kal1</italic> gene, which is the most frequently observed genetic abnormality in males affected by this condition.</p>
      </sec>
      <sec id="article-23284.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Hypopituitarism is&#x000a0;categorized as a rare disorder by the National Institute of Health (NIH), with limited data&#x000a0;available on the incidence and prevalence of the condition.&#x000a0;A study conducted by Regal et al in Northwestern Spain reported a prevalence of 45.5 cases per 100,000 population.<xref ref-type="bibr" rid="article-23284.r15">[15]</xref><xref ref-type="bibr" rid="article-23284.r16">[16]</xref></p>
      </sec>
      <sec id="article-23284.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Evidence suggests hypopituitarism develops when 75% of the pituitary gland is compromised. The clinical manifestations of hypopituitarism can vary from subtle and ill-defined to severe with an acute presentation. Conditions such as Sheehan syndrome, pituitary apoplexy, pituitary infection, hypophysitis, and traumatic brain injury present with acute findings.<xref ref-type="bibr" rid="article-23284.r17">[17]</xref><xref ref-type="bibr" rid="article-23284.r18">[18]</xref><xref ref-type="bibr" rid="article-23284.r19">[19]</xref></p>
        <p>The presenting signs and symptoms of hypopituitarism may be attributed to various factors, including deficiencies in pituitary hormones, the mass effects associated with pituitary tumors, and characteristics of the underlying causative disease.</p>
        <p>The symptoms associated with hormonal deficiencies are listed below.<xref ref-type="bibr" rid="article-23284.r20">[20]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>ACTH deficiency:&#x000a0;ACTH deficiency results in adrenal insufficiency.</p>
          </list-item>
          <list-item>
            <p>TSH deficiency: TSH deficiency leads to hypothyroidism.</p>
          </list-item>
          <list-item>
            <p>Gonadotropin deficiency:&#x000a0;Gonadotropin deficiency leads to hypogonadism.</p>
          </list-item>
          <list-item>
            <p>GH deficiency: GH deficiency in children can result in poor growth and short stature. Although this hormonal deficiency is typically asymptomatic in adults, some individuals may experience fatigue and weakness.</p>
          </list-item>
          <list-item>
            <p>ADH deficiency: ADH deficiency leads to diabetes insipidus, characterized by symptoms such as polydipsia and polyuria.</p>
          </list-item>
        </list>
        <p>Visual field defects, such as bitemporal hemianopsia, are the most common manifestation of pituitary tumor mass effects, followed by unilateral defects.&#x000a0;Patients may develop headaches as a secondary symptom caused by these mass lesions.</p>
        <p>Physical examination of patients may not yield significant findings, as the presentation of hypopituitarism is typically subtle. However, variable features may be present due to the involvement of different target hormones, resulting in the following conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypothyroidism: Symptoms may include a small and soft thyroid gland, dry and coarse skin, hair thinning and alopecia, delayed tendon reflexes, cold skin with reduced sweating, and non-pitting type edema.</p>
          </list-item>
          <list-item>
            <p>Adrenal insufficiency: Common symptoms include fatigue and postural hypotension.</p>
          </list-item>
          <list-item>
            <p>Hypogonadism: In men, this condition can manifest as small and atrophied testes, whereas in women, it may lead to the loss of axillary and pubic hair.</p>
          </list-item>
          <list-item>
            <p>Neurological and ophthalmic involvement: This can result in a loss of visual acuity, extraocular paresis, and bitemporal hemianopsia.</p>
          </list-item>
          <list-item>
            <p>Diabetes insipidus:&#x000a0;Symptoms include hypernatremia, polyuria, and diluted urine.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23284.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>A secretory pituitary tumor can lead to an overproduction of the hormone specific to the tumor, causing symptoms related to excess hormone levels. Meanwhile, other pituitary hormones may become deficient.<xref ref-type="bibr" rid="article-23284.r21">[21]</xref><xref ref-type="bibr" rid="article-23284.r22">[22]</xref><xref ref-type="bibr" rid="article-23284.r23">[23]</xref><xref ref-type="bibr" rid="article-23284.r24">[24]</xref></p>
        <p>
<bold>Investigations</bold>
</p>
        <p><bold>Laboratory investigations:</bold> Initial testing involves assessing baseline levels of pituitary hormones and&#x000a0;hormones produced by the target glands. Because hormone levels can fluctuate based on several factors, such as the time of day, season, and pulsatile secretion of certain pituitary hormones, assessing the baseline levels may not always provide useful information. In such cases, dynamic function testing can help confirm the presence of any biochemical deficiency or excess of a particular pituitary hormone.</p>
        <p>Dynamic function testing involves the administration of a stimulatory agent that would typically trigger an increase in the secretion of the hormone in question. The patient's blood levels are measured before and after administering this stimulant. Measurements are taken at defined intervals to assess whether a proper response to the stimulation has occurred.<xref ref-type="bibr" rid="article-23284.r25">[25]</xref></p>
        <p><bold>Insulin tolerance test (ITT):</bold>&#x000a0;ITT is considered the most reliable and historical standard provocative test for assessing deficiencies of both GH and ACTH levels in patients. Baseline measurements of cortisol, growth hormone, and glucose are obtained after an overnight fast for individuals undergoing ITT. Subsequently, an intravenous (IV) insulin dose of 0.1 or 0.05 U/kg is administered to patients, and hormone and glucose samples are collected at regular intervals. The plasma glucose level should ideally decrease to 40 mg/dL during the test within 30 to 45 minutes or 50% from the baseline level. The test is concluded by administering IV dextrose and monitoring the patient's condition for 90 minutes. Cortisol levels above 20 &#x000b5;g/dL and GH levels between 5 and 10 ng/mL demonstrate an adequate response. Notably, an&#x000a0;ITT&#x000a0;should not be performed in&#x000a0;individuals&#x000a0;with cardiac&#x000a0;conditions or epilepsy.&#x000a0;</p>
        <p><bold>ACTH stimulation test:</bold> This test is an alternative to ITT when the latter poses a health risk due to severe hypoglycemia. This test assesses the function of the hypothalamic-pituitary-adrenal&#x000a0;axis. Instead of insulin, synthetic ACTH is administered via IV or intramuscular (IM) route at either 1 or 250 mcg, which is the most commonly used dose. Cortisol levels are measured before administering ACTH to patients at 30-, 60-, and 90-minute&#x000a0;intervals. A normal response is indicated when cortisol levels exceed 18 mcg/dL.<xref ref-type="bibr" rid="article-23284.r26">[26]</xref></p>
        <p><bold>Modern combined test:</bold>&#x000a0;This test represents a comprehensive approach to hormone assessment. During this test, the patient receives GH-releasing hormone (GHRH), cortisol-releasing hormone (CRH), gonadotropin-releasing hormone (GnRH), and thyroid-releasing hormone (TRH) as provocative stimuli. The GH, TSH, ACTH, cortisol, LH, and FSH levels are measured at baseline and specified time intervals thereafter.&#x000a0;The doses of each stimulating hormone are as follows: GHRH 1.0 &#x000b5;g/kg,&#x000a0;CRH 1.0 &#x000b5;g/kg,&#x000a0;GnRH 100 &#x000b5;g, and&#x000a0;TRH 200 &#x000b5;g.&#x000a0;However, it is noteworthy that this test rarely applies&#x000a0;in clinical practice due to its infrequent necessity.</p>
        <p><bold>Radiological investigations:</bold>&#x000a0;Imaging studies of the pituitary involve&#x000a0;using MRI with gadolinium enhancement, which is the preferred method for visualizing the pituitary, primarily to detect the presence of a mass lesion. Visual field defects must be assessed if a pituitary mass is suspected to be the underlying cause of hypopituitarism.</p>
      </sec>
      <sec id="article-23284.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The primary objective and management strategies for hypopituitarism are&#x000a0;customized to address the condition's underlying cause. Surgical removal of mass lesions is critical, and concurrent medical conditions also require appropriate treatment.&#x000a0;Many patients may require hormone replacement therapy to restore hormonal balance and alleviate associated symptoms.<xref ref-type="bibr" rid="article-23284.r27">[27]</xref></p>
        <p>
<bold>ACTH deficit</bold>
</p>
        <p>Corticosteroid replacement should be initiated before the thyroid hormone replacement to prevent the risk of precipitating an adrenal crisis. Hydrocortisone is typically recommended at 10 to 20 mg in the morning and 5 to 10 mg in the afternoon. Some endocrinologists advocate for 3 daily doses&#x000a0;in symptomatic patients to imitate the physiological hormonal secretion. However, the last&#x000a0;dose, whether the second or third, should not be administered to patients at night&#x000a0;to prevent&#x000a0;insomnia.&#x000a0;Occasionally, patients respond well to once-daily dosing, which can be considered individually.<xref ref-type="bibr" rid="article-23284.r28">[28]</xref> Prednisone may also be used once daily. Increased dosages of corticosteroids are required during stressful situations, surgery, or pregnancy.</p>
        <p>
<bold>TSH deficit</bold>
</p>
        <p>Individuals at an advanced age or those with cardiac disease require the thyroid hormone, also called <italic toggle="yes">L</italic>-thyroxine, replacement therapy. Treatment initiation generally involves a low dose of 25 &#x000b5;g/d of&#x000a0;<italic toggle="yes">L</italic>-thyroxine, followed by gradual adjustments based on biochemical&#x000a0;results and clinical indicators. As TSH is no longer a reliable marker, peripheral hormone levels of free or total thyroxine (T4) should be assessed.</p>
        <p>
<bold>FSH/LH deficit</bold>
</p>
        <p>In men, testosterone replacement can be delivered through various methods, including gels, patches, oral medications, or IM injections. Prostate-specific antigen and hemoglobin levels should be closely monitored in this group.<xref ref-type="bibr" rid="article-23284.r29">[29]</xref></p>
        <p>In women, estrogen and progesterone hormone replacement therapy can be administered IM, orally, or transdermally. Hormone levels should be carefully monitored and normalized across all axes in this group, not just for the reproductive system, especially when fertility is desired.<xref ref-type="bibr" rid="article-23284.r30">[30]</xref></p>
        <p>For men seeking fertility,&#x000a0;human chorionic gonadotropin&#x000a0;(HCG) can augment testosterone levels and improve semen quality. If this approach is unsuccessful after one year, adding concomitant therapy with human menopausal gonadotropin (HMG) and recombinant FSH could further enhance fertility. Specialty fertility clinics are dedicated to further evaluating and managing these patients.<xref ref-type="bibr" rid="article-23284.r31">[31]</xref></p>
        <p>
<bold>GH deficit</bold>
</p>
        <p>In contrast to the well-defined role of synthetic GH replacement therapy in treating GH deficiency&#x02013;related short stature in children, the role of GH replacement therapy for adults with GH deficiency has not been firmly established. In pediatric cases, synthetic&#x000a0;GH&#x000a0;treatments, such as somatotropin, are utilized, and the therapy is adjusted according to&#x000a0;insulin-like growth factor 1 (IGF-1) levels. The objective of the treatment is to attain the individual's complete adult stature.&#x000a0;Further evaluation is conducted after puberty to determine whether GH replacement therapy should continue until the individual reaches adulthood.</p>
        <p>
<bold>ADH deficit</bold>
</p>
        <p>ADH replacement with intranasal or oral desmopressin,&#x000a0;a synthetic analog of vasopressin, aids in stabilizing the water balance and addressing polyuria in patients. Maintaining sodium levels within the normal range is essential. Monitoring urine-specific gravity and osmolality helps validate the effectiveness of ADH replacement and ensures appropriate water regulation. These measurements are crucial indicators to confirm the efficacy of the treatment regimen.</p>
      </sec>
      <sec id="article-23284.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>In complex situations, a diagnosis of hypopituitarism may be overlooked or delayed, especially when normal pituitary hormone levels are misinterpreted within the context of suboptimal target organ hormone levels. However, clinical treatment should be initiated in cases of suspected adrenal insufficiency without waiting for definitive biochemical evidence.</p>
        <p>The differential diagnoses that may be considered when assessing for hypopituitarism in patients include primary hypothyroidism,&#x000a0;Kallmann syndrome, pituitary macroadenomas, hyponatremia, and autoimmune polyglandular syndrome types 1, 2, and 3.<xref ref-type="bibr" rid="article-23284.r32">[32]</xref></p>
      </sec>
      <sec id="article-23284.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients in stable condition and can adhere to hormone replacement therapy typically have a favorable prognosis. Mortality rates increase in patients experiencing acute decompensation and critical states. The extent of morbidity varies and is contingent on the hormone deficiency type.</p>
        <p>The systemic effects of hypopituitarism vary depending on the extent of pituitary involvement. Certain clinical states that result from the acute decline in pituitary production may increase the mortality risk. For instance, ACTH deficiency can lead to an adrenal crisis, whereas TSH deficiency may cause myxedema coma, potentially resulting in death.<xref ref-type="bibr" rid="article-23284.r33">[33]</xref></p>
      </sec>
      <sec id="article-23284.s10" sec-type="Complications">
        <title>Complications</title>
        <p>Other hormonal deficiencies that often accompany hypopituitarism can contribute to developing secondary diseases. For instance, a human&#x000a0;GH (HGH)&#x000a0;deficiency is associated with obesity, elevated cholesterol levels, and metabolic syndrome. Likewise, estradiol deficiency can potentially lead to osteoporosis.<xref ref-type="bibr" rid="article-23284.r34">[34]</xref></p>
      </sec>
      <sec id="article-23284.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education should primarily emphasize the necessity of lifelong hormone replacement therapy, the importance of increased glucocorticoid doses during stressful situations, and the need for prompt medical attention as deemed necessary. Furthermore, regular monitoring is essential to prevent inadequate or excessive hormone replacement.</p>
        <p>Patients should always carry a form of identification, such as a medical alert bracelet or necklace, that provides details about their medical condition to ensure an efficient and prompt medical response during emergencies. In addition,&#x000a0;patients may also require access to a vial of hydrocortisone 100 mg and a syringe, both at home and while traveling, to help them manage their condition during emergencies. These precautions are essential to mitigate potential complications and&#x000a0;ensure appropriate care in critical situations.</p>
      </sec>
      <sec id="article-23284.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Diagnosing and treating hypopituitarism&#x000a0;necessitate collaboration among an interprofessional healthcare team comprising a neurosurgeon, endocrinologist, pathologist, radiologist, primary care provider, nurse practitioner, pharmacist, and ophthalmologist.&#x000a0;Discussions and shared decision-making between patients and their healthcare providers are crucial for determining the most suitable treatment approach and improving patient outcomes.</p>
        <p>The management of hypopituitarism is contingent on its underlying cause. Initial interventions should target the root cause, which may involve surgical removal of mass lesions and the treatment of concurrent medical conditions.&#x000a0;Many patients may require hormone replacement therapy. The prognosis for most patients with hypopituitarism is generally favorable. However, individuals with neurological deficits may experience partial deficits even after treatment.<xref ref-type="bibr" rid="article-23284.r1">[1]</xref><xref ref-type="bibr" rid="article-23284.r35">[35]</xref><xref ref-type="bibr" rid="article-23284.r36">[36]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-23284.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23284&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23284">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/hormones-and-body-chemistry/hypopituitarism/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23284">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23284/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23284">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23284.s14">
        <title>References</title>
        <ref id="article-23284.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Follow-Up Studies of Gamma Knife Radiosurgery for Postsurgical Nonfunctioning Pituitary Adenomas.</article-title>
            <source>World Neurosurg</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>124</volume>
            <fpage>e715</fpage>
            <page-range>e715-e723</page-range>
            <pub-id pub-id-type="pmid">30660894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thompson</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Costello</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Crowley</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Management of hypothalamic disease in patients with craniopharyngioma.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>90</volume>
            <issue>4</issue>
            <fpage>506</fpage>
            <page-range>506-516</page-range>
            <pub-id pub-id-type="pmid">30614015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qiao</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Excess mortality after craniopharyngioma treatment: are we making progress?</article-title>
            <source>Endocrine</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-37</page-range>
            <pub-id pub-id-type="pmid">30569259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>VanKoevering</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Sabetsarvestani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Barkan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mierzwa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McKean</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>Pituitary Dysfunction after Radiation for Anterior Skull Base Malignancies: Incidence and Screening.</article-title>
            <source>J Neurol Surg B Skull Base</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>81</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-81</page-range>
            <pub-id pub-id-type="pmid">32021753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Dalmazi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ippolito</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lupi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Caturegli</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment.</article-title>
            <source>Expert Rev Endocrinol Metab</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>381</fpage>
            <page-range>381-398</page-range>
            <pub-id pub-id-type="pmid">31842671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alexandraki</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Management of Hypopituitarism.</article-title>
            <source>J Clin Med</source>
            <year>2019</year>
            <month>Dec</month>
            <day>05</day>
            <volume>8</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">31817511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanie</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Iguchi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bando</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Urai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shichi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fujita</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Suda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fukuoka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.</article-title>
            <source>Cancer Immunol Immunother</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>70</volume>
            <issue>12</issue>
            <fpage>3669</fpage>
            <page-range>3669-3677</page-range>
            <pub-id pub-id-type="pmid">33977343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prodam</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Caputo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mele</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marzullo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aimaretti</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Insights into non-classic and emerging causes of hypopituitarism.</article-title>
            <source>Nat Rev Endocrinol</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>114</fpage>
            <page-range>114-129</page-range>
            <pub-id pub-id-type="pmid">33247226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takahashi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>MECHANISMS IN ENDOCRINOLOGY: Autoimmune hypopituitarism: novel mechanistic insights.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>182</volume>
            <issue>4</issue>
            <fpage>R59</fpage>
            <page-range>R59-R66</page-range>
            <pub-id pub-id-type="pmid">31999621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caputo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mele</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Prodam</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Marzullo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aimaretti</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Clinical picture and the treatment of TBI-induced hypopituitarism.</article-title>
            <source>Pituitary</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>261</fpage>
            <page-range>261-269</page-range>
            <pub-id pub-id-type="pmid">30929220</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kgosidialwa</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Agha</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Hypopituitarism post traumatic brain injury (TBI): review.</article-title>
            <source>Ir J Med Sci</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>188</volume>
            <issue>4</issue>
            <fpage>1201</fpage>
            <page-range>1201-1206</page-range>
            <pub-id pub-id-type="pmid">30931510</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pangal</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Chesney</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Memel</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Bonney</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Strickland</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Carmichael</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shiroishi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jason Liu</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Zada</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Pituitary Apoplexy Case Series: Outcomes After Endoscopic Endonasal Transsphenoidal Surgery at a Single Tertiary Center.</article-title>
            <source>World Neurosurg</source>
            <year>2020</year>
            <month>May</month>
            <volume>137</volume>
            <fpage>e366</fpage>
            <page-range>e366-e372</page-range>
            <pub-id pub-id-type="pmid">32032792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gregory</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Dattani</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>The Molecular Basis of Congenital Hypopituitarism and Related Disorders.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2020</year>
            <month>Jun</month>
            <day>01</day>
            <volume>105</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">31702014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xatzipsalti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Voutetakis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stamoyannou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Kanaka-Gantenbein</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Congenital Hypopituitarism: Various Genes, Various Phenotypes.</article-title>
            <source>Horm Metab Res</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>81</fpage>
            <page-range>81-90</page-range>
            <pub-id pub-id-type="pmid">30759489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malik</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kiran</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Rashid</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Mawani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gulab</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Masood</surname>
                <given-names>MQ</given-names>
              </name>
              <name>
                <surname>Islam</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Hypopituitarism other than sellar and parasellar tumors or traumatic brain injury assessed in a tertiary hospital.</article-title>
            <source>Pak J Med Sci</source>
            <year>2019</year>
            <season>Jul-Aug</season>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>1149</fpage>
            <page-range>1149-1154</page-range>
            <pub-id pub-id-type="pmid">31372159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Regal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>P&#x000e1;ramo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sierra</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Garcia-Mayor</surname>
                <given-names>RV</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>2001</year>
            <month>Dec</month>
            <volume>55</volume>
            <issue>6</issue>
            <fpage>735</fpage>
            <page-range>735-40</page-range>
            <pub-id pub-id-type="pmid">11895214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdelmannan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Aron</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Incidentally discovered pituitary masses: pituitary incidentalomas.</article-title>
            <source>Expert Rev Endocrinol Metab</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>253</fpage>
            <page-range>253-264</page-range>
            <pub-id pub-id-type="pmid">30764049</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnaldi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cardinaletti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trementino</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tirabassi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Boscaro</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pituitary-directed medical treatment of Cushing's disease.</article-title>
            <source>Expert Rev Endocrinol Metab</source>
            <year>2009</year>
            <month>May</month>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>263</fpage>
            <page-range>263-272</page-range>
            <pub-id pub-id-type="pmid">30743797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Healy</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>TPP</given-names>
              </name>
              <name>
                <surname>McKenna</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis, misdiagnosis and management of hyperprolactinemia.</article-title>
            <source>Expert Rev Endocrinol Metab</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>123</fpage>
            <page-range>123-132</page-range>
            <pub-id pub-id-type="pmid">30743775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jullien</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Saveanu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vergier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Marquant</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Quentien</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Castinetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Galon-Faure</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brauner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marrakchi Turki</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Tauber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>El Kholy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Linglart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rodien</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fedala</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Bergada</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cortet-Rudelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Polak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nicolino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stuckens</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barlier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Reynaud</surname>
                <given-names>R</given-names>
              </name>
              <collab>Genhypopit Network</collab>
            </person-group>
            <article-title>Clinical lessons learned in constitutional hypopituitarism from two decades of experience in a large international cohort.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>94</volume>
            <issue>2</issue>
            <fpage>277</fpage>
            <page-range>277-289</page-range>
            <pub-id pub-id-type="pmid">33098107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lamas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Mart&#x000ed;nez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>C&#x000e1;mara</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fajardo-Montanana</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Viguera</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Aranda</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Silent somatotropinomas.</article-title>
            <source>Minerva Endocrinol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>44</volume>
            <issue>2</issue>
            <fpage>137</fpage>
            <page-range>137-142</page-range>
            <pub-id pub-id-type="pmid">30531696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Hutchinson</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>A neurosurgical approach to traumatic brain injury and post-traumatic hypopituitarism.</article-title>
            <source>Pituitary</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>332</fpage>
            <page-range>332-337</page-range>
            <pub-id pub-id-type="pmid">30483919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernabeu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Aller</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>&#x000c1;lvarez-Escol&#x000e1;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fajardo-Monta&#x000f1;ana</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>G&#x000e1;lvez-Moreno</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Guill&#x000ed;n-Amarelle</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sesmilo</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Criteria for diagnosis and postoperative control of acromegaly, and screening and management of its comorbidities: Expert consensus.</article-title>
            <source>Endocrinol Diabetes Nutr (Engl Ed)</source>
            <year>2018</year>
            <month>May</month>
            <volume>65</volume>
            <issue>5</issue>
            <fpage>297</fpage>
            <page-range>297-305</page-range>
            <pub-id pub-id-type="pmid">29653911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Delgado-L&#x000f3;pez</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Pi-Barrio</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Due&#x000f1;as-Polo</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Pascual-Llorente</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gord&#x000f3;n-Bola&#x000f1;os</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Recurrent non-functioning pituitary adenomas: a review on the new pathological classification, management guidelines and treatment options.</article-title>
            <source>Clin Transl Oncol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>10</issue>
            <fpage>1233</fpage>
            <page-range>1233-1245</page-range>
            <pub-id pub-id-type="pmid">29623588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>SY</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Treatment of Hypopituitarism.</article-title>
            <source>Endocrinol Metab (Seoul)</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>443</fpage>
            <page-range>443-55</page-range>
            <pub-id pub-id-type="pmid">26790380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cho</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Jang</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SY</given-names>
              </name>
            </person-group>
            <article-title>Different cut-off values of the insulin tolerance test, the high-dose short Synacthen test (250 &#x003bc;g) and the low-dose short Synacthen test (1 &#x003bc;g) in assessing central adrenal insufficiency.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>81</volume>
            <issue>1</issue>
            <fpage>77</fpage>
            <page-range>77-84</page-range>
            <pub-id pub-id-type="pmid">24382108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Higham</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Johannsson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shalet</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Hypopituitarism.</article-title>
            <source>Lancet</source>
            <year>2016</year>
            <month>Nov</month>
            <day>12</day>
            <volume>388</volume>
            <issue>10058</issue>
            <fpage>2403</fpage>
            <page-range>2403-2415</page-range>
            <pub-id pub-id-type="pmid">27041067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Hormone replacement therapy in hypopituitarism.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2004</year>
            <month>May</month>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>1023</fpage>
            <page-range>1023-31</page-range>
            <pub-id pub-id-type="pmid">15155105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Osterberg</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Bernie</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ramasamy</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Risks of testosterone replacement therapy in men.</article-title>
            <source>Indian J Urol</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-7</page-range>
            <pub-id pub-id-type="pmid">24497673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vila</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fleseriu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Fertility and Pregnancy in Women With Hypopituitarism: A Systematic Literature Review.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2020</year>
            <month>Mar</month>
            <day>01</day>
            <volume>105</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">31652320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fainberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kashanian</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in understanding and managing male infertility.</article-title>
            <source>F1000Res</source>
            <year>2019</year>
            <volume>8</volume>
            <pub-id pub-id-type="pmid">31143441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahaly</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Polyglandular autoimmune syndromes.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>161</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-20</page-range>
            <pub-id pub-id-type="pmid">19411300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pappachan</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Raskauskiene</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kutty</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Clayton</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>100</volume>
            <issue>4</issue>
            <fpage>1405</fpage>
            <page-range>1405-11</page-range>
            <pub-id pub-id-type="pmid">25658016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Aken</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Lamberts</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of hypopituitarism: an update.</article-title>
            <source>Pituitary</source>
            <year>2005</year>
            <volume>8</volume>
            <issue>3-4</issue>
            <fpage>183</fpage>
            <page-range>183-91</page-range>
            <pub-id pub-id-type="pmid">16508719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Endocrinological Outcomes of Intraoperative MRI-Guided Endoscopic Transsphenoidal Surgery for Non-Functioning Pituitary Adenoma.</article-title>
            <source>Turk Neurosurg</source>
            <year>2019</year>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>635</fpage>
            <page-range>635-642</page-range>
            <pub-id pub-id-type="pmid">30649793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23284.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jamshidi</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Beer-Furlan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Prevedello</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Sahyouni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Elzoghby</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Safain</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Carrau</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Jane</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Laws</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>A modern series of subdiaphragmatic craniopharyngiomas.</article-title>
            <source>J Neurosurg</source>
            <year>2019</year>
            <month>Aug</month>
            <day>01</day>
            <volume>131</volume>
            <issue>2</issue>
            <fpage>526</fpage>
            <page-range>526-531</page-range>
            <pub-id pub-id-type="pmid">30485192</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
